Regulus Therapeutics Inc. (NASDAQ:RGLS) – Research analysts at Wedbush cut their Q3 2017 earnings estimates for Regulus Therapeutics in a research report issued to clients and investors on Monday. Wedbush analyst L. Moussatos now anticipates that the biopharmaceutical company will earn ($0.14) per share for the quarter, down from their previous estimate of ($0.10). Wedbush currently has a “Ourperform” rating and a $4.00 target price on the stock. Wedbush also issued estimates for Regulus Therapeutics’ Q4 2017 earnings at ($0.13) EPS, FY2017 earnings at ($0.88) EPS, Q2 2018 earnings at ($0.12) EPS, Q3 2018 earnings at ($0.12) EPS, Q4 2018 earnings at ($0.12) EPS, FY2018 earnings at ($0.49) EPS, FY2019 earnings at ($0.52) EPS, FY2020 earnings at ($0.58) EPS and FY2021 earnings at ($0.20) EPS.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.10. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/09/wedbush-comments-on-regulus-therapeutics-inc-s-q3-2017-earnings-rgls.html.

A number of other equities research analysts also recently issued reports on RGLS. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a report on Wednesday, August 2nd. Chardan Capital cut shares of Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 2nd. Zacks Investment Research cut shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. BMO Capital Markets set a $1.00 target price on shares of Regulus Therapeutics and gave the stock a “hold” rating in a research report on Monday, June 12th. Finally, ValuEngine cut shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $3.58.

Regulus Therapeutics (RGLS) opened at 0.9516 on Wednesday. The firm’s market capitalization is $50.61 million. Regulus Therapeutics has a 12-month low of $0.86 and a 12-month high of $3.81. The firm has a 50-day moving average of $1.00 and a 200 day moving average of $1.34.

A number of institutional investors have recently added to or reduced their stakes in the company. Teachers Advisors LLC boosted its stake in shares of Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 9,804 shares during the last quarter. LMR Partners LLP acquired a new stake in Regulus Therapeutics during the second quarter valued at $164,000. Tudor Investment Corp ET AL boosted its stake in Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 61,373 shares in the last quarter. Wedbush Securities Inc. boosted its stake in Regulus Therapeutics by 10.3% in the second quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 18,600 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock valued at $1,291,000 after buying an additional 93,295 shares in the last quarter. Hedge funds and other institutional investors own 21.09% of the company’s stock.

In other news, Director William H. Rastetter acquired 274,725 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were purchased at an average price of $0.91 per share, for a total transaction of $249,999.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph P. Hagan acquired 219,780 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was purchased at an average price of $0.91 per share, for a total transaction of $199,999.80. Following the acquisition, the insider now directly owns 241,297 shares of the company’s stock, valued at approximately $219,580.27. The disclosure for this purchase can be found here. Insiders have acquired 549,450 shares of company stock valued at $500,000 over the last ninety days. Insiders own 4.80% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Earnings History and Estimates for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.